Antibody-drug conjugates have been around for more than 2 decades and there's now more than a dozen on the market worldwide. So why all of a sudden is big pharma scrambling to strike new, billion-dollar licensing deals in the ADC space? During Fierce Biotech Next Gen we will dive into the new frontier of ADCs: where they are headed in the clinic—and whether they have a future beyond cancer.

Ready to join us on June 13th at this free virtual event? Make sure to secure your spot by registering today!

FEATURED SESSION

Panel: The ABCs of ADCs: What's next?

Dr. Mark Rutstein

Head of Global Oncology Clinical Development

Daiichi Sankyo

Megan O' Meara, M.D.

SVP and Head of Clinical Development

Seagen

Timothy B. Lowinger, PhD

Chief Science and Technology Officer

Mersana

David Weinstock

VP of Discovery Oncology

Merck

VIEW THE FULL AGENDA

Thank You to Our 2023 Partners

PLATINUM

GOLD

SUPPORTER

Interested in Partnering?

Position your company as a thought leader, promote your brand and engage with top decision-makers. Complete the inquiry form here and a member of our team will follow up with you shortly!

If you no longer wish to receive promotion on this event, simply unsubscribe.
Refer to our Privacy Policy.

Fierce Life Sciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017